Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.

2.

Oncogenic activation of androgen receptor.

Kung HJ, Evans CP.

Urol Oncol. 2009 Jan-Feb;27(1):48-52. doi: 10.1016/j.urolonc.2008.06.002. Review.

3.

Targeting tyrosine kinases and autophagy in prostate cancer.

Kung HJ.

Horm Cancer. 2011 Feb;2(1):38-46. doi: 10.1007/s12672-010-0053-3. Epub 2010 Dec 2. Review.

4.

Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.

Mahajan K, Mahajan NP.

J Cell Physiol. 2010 Aug;224(2):327-33. doi: 10.1002/jcp.22162. Review.

5.

Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases.

Gelman IH.

Int J Biol Sci. 2014 Jun 5;10(6):620-6. doi: 10.7150/ijbs.8264. eCollection 2014. Review.

6.

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

Montero JC, Seoane S, OcaƱa A, Pandiella A.

Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13. Review.

7.

ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.

Mahajan K, Mahajan NP.

Oncogene. 2015 Aug 6;34(32):4162-7. doi: 10.1038/onc.2014.350. Epub 2014 Oct 27. Review.

8.

ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation.

Mahajan K, Mahajan NP.

Cancer Lett. 2013 Sep 28;338(2):185-92. doi: 10.1016/j.canlet.2013.04.004. Epub 2013 Apr 15. Review.

9.

AR, the cell cycle, and prostate cancer.

Balk SP, Knudsen KE.

Nucl Recept Signal. 2008 Feb 1;6:e001. doi: 10.1621/nrs.06001. Review.

10.

Src signaling pathways in prostate cancer.

Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG.

Cancer Metastasis Rev. 2014 Sep;33(2-3):595-606. doi: 10.1007/s10555-013-9481-1. Review.

11.

Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.

Roskoski R Jr.

Pharmacol Res. 2015 Apr;94:9-25. doi: 10.1016/j.phrs.2015.01.003. Epub 2015 Feb 3. Review.

PMID:
25662515
12.

Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.

Sadar MD.

Cancer Res. 2011 Feb 15;71(4):1208-13. doi: 10.1158/0008-5472.CAN_10-3398. Epub 2011 Feb 1. Review.

13.

Novel therapies for metastatic castrate-resistant prostate cancer.

Dayyani F, Gallick GE, Logothetis CJ, Corn PG.

J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75. doi: 10.1093/jnci/djr362. Epub 2011 Sep 13. Review.

14.

Androgen receptor phosphorylation: biological context and functional consequences.

Koryakina Y, Ta HQ, Gioeli D.

Endocr Relat Cancer. 2014 Aug;21(4):T131-45. doi: 10.1530/ERC-13-0472. Epub 2014 Jan 14. Review.

15.

Regulation of connexin43 function by activated tyrosine protein kinases.

Lau AF, Kurata WE, Kanemitsu MY, Loo LW, Warn-Cramer BJ, Eckhart W, Lampe PD.

J Bioenerg Biomembr. 1996 Aug;28(4):359-68. Review.

PMID:
8844333
16.

Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Ahluwalia MS, de Groot J, Liu WM, Gladson CL.

Cancer Lett. 2010 Dec 8;298(2):139-49. doi: 10.1016/j.canlet.2010.08.014. Review.

17.

Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer.

Elsberger B.

Crit Rev Oncol Hematol. 2014 Mar;89(3):343-51. doi: 10.1016/j.critrevonc.2013.12.009. Epub 2013 Dec 15. Review.

PMID:
24388104
18.

Fyn: a novel molecular target in cancer.

Saito YD, Jensen AR, Salgia R, Posadas EM.

Cancer. 2010 Apr 1;116(7):1629-37. doi: 10.1002/cncr.24879. Review.

19.

Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.

Ojemuyiwa MA, Madan RA, Dahut WL.

Expert Opin Emerg Drugs. 2014 Dec;19(4):459-70. doi: 10.1517/14728214.2014.969239. Epub 2014 Oct 25. Review.

PMID:
25345821
20.

Recent androgen receptor antagonists in prostate cancer.

Lu X, Dun K, Wang Y, Yang Y, You Q, Li Z.

Mini Rev Med Chem. 2014;14(8):655-63. Review.

PMID:
24958215
Items per page

Supplemental Content

Write to the Help Desk